Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2024

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2024 – By Type (Pegfilgrastim, Lenograstim, Filgrastim, Other Types), By Product (Tablet, Capsule, Other Products), By Application (Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
G-CSF (Granulocyte Colony Stimulating Factors) Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

G-CSF (Granulocyte Colony Stimulating Factors) Market Definition And Segments

G-CSF (granulocyte colony stimulating factors) market refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.

The main types of G-CSF (granulocyte colony-stimulating factors) market are lenograstim, filgrastim, Pegfilgrastim, and others. Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablets, capsules, and others and are used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, and others.

The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product: Tablet, Capsule, Other Products

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

The G-CSF (granulocyte colony stimulating factors) market size has grown steadily in recent years. It will grow from $8.84 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to increase in cancer prevalence, strong economic growth in emerging markets, increased healthcare expenditure, increase in pharmaceutical R& expenditure and government initiatives.

The G-CSF (granulocyte colony stimulating factors) market size is expected to see steady growth in the next few years. It will grow to $10.98 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis granulocyte colony-stimulating factor (g-CSF), rise in healthcare expenditure, high potential of emerging economies, technology advances and high penetration of the biosimilar drugs. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative drugs, increasing focus on M&A growth strategies, establishing strategic partnerships and developments activities in new drug developments and focusing efforts towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Rising Prevalence Of Cancer Drives G-CS Market Growth

The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in January 2023, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. G-CSF (granulocyte colony stimulating factor) is a class of growth factors that produce white blood cells in the bone marrow to minimize the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF (granulocyte colony stimulating factor) market.

Rising Healthcare Expenditure Fuels G-CS Market Growth

Rising healthcare expenditure is expected to propel the growth of the G-CSF (granulocyte colony stimulating factor) market going forward. Healthcare expenditure refers to the amount of money spent on healthcare goods and services, including medical equipment, pharmaceuticals, hospital care, physician services, and public health activities. Healthcare expenditure plays a critical role in the G-CSF market, impacting the cost-effectiveness, adoption, cost savings, market growth, and budget-saving potential of G-CSF products. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021–2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, rising healthcare expenditure is driving the growth of the G-CSF (granulocyte colony stimulating factors) market.

Major companies operating in the G-CSF (granulocyte colony stimulating factors) market report are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd., BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

High Costs Limit Growth Of G-CSF Market

The high cost is a key factor limiting the growth of the G-CSF (granulocyte colony stimulating factor) market. Improved chemotherapy administration is responsible for the rise in immediate medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the cost of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (granulocyte colony stimulating factor) market.

Strategic Collaborations Drive Innovation In G-CSF Market

Companies in the G-CSF (granulocyte colony stimulating factor) market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore-based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation.

Focus On Automation With Automated Injection Devices

Major companies operating in the G-CSF (granulocyte colony stimulating factor) market are integrating their efforts into introducing automated products, such as automated injection devices, to gain a competitive edge in the market. An automated injection device is a medical device that automatically delivers a dose of G-CSF into the body at a specific time after chemotherapy. For instance, in December 2022, Kyowa Kirin Co. Ltd., a Japan-based Japanese pharmaceutical company, launched G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a long-acting G-CSF preparation for decreasing the incidence of febrile neutropenia in patients receiving cancer chemotherapy. It is an automated injection device for G-Lasta that works by giving the patient a dose of G-Lasta about 27 hours after the device is connected. It can be attached to patients on the day of chemotherapy, eliminating the need for an additional outpatient visit the following day to administer G-Lasta.

Novartis Acquires Gyroscope Therapeutics To Expand Portfolio And Ophthalmic Innovation

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF drugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases.

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2023. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the G-CSF (granulocyte colony stimulating factors) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

G-CSF (Granulocyte Colony Stimulating Factors) Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $9.17 billion
Revenue Forecast In 2033 $10.98 billion
Growth Rate CAGR of 4.6% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types
2) By Product: Tablet, Capsule, Other Products
3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Amgen Inc.; Coherus Biosciences Inc.; Sandoz; Biocon/Mylan; Teva Pharmaceuticals Inc.; Chugai Pharma; Intalfarmaco Group; Pfizer; Sun Pharmaceutical Industries Limited; BeyondSpring Inc.; Kyowa Hakko Kirin Co. Ltd; BioCad; Stada Arzneimittel; Dong-A Socio Group; Dr. Reddy's Laboratories; Celltrion Inc.; Emcure Pharmaceuticals; Accord Healthcare UK; Intas Pharmaceuticals; Spectrum Pharmaceuticals; Apobiologix; Apotex Inc.; Eurofarma Laboratórios; BIOPHARMA-MEA; NeoTX; AID Genomics Limited; GlaxoSmithKline plc; AstraZeneca; Merck Sharp & Dohme Corp.; Julphar; Sanofi; Novo Nordisk A/S; Bayer; Kitov Pharma Limited; CureTech Ltd.; Neopharma; Cipla.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. G-CSF (Granulocyte Colony Stimulating Factors) Market Characteristics

    3. G-CSF (Granulocyte Colony Stimulating Factors) Market Trends And Strategies

    4. G-CSF (Granulocyte Colony Stimulating Factors) Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Size and Growth

    5.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. G-CSF (Granulocyte Colony Stimulating Factors) Market Segmentation

    6.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Pegfilgrastim

    Lenograstim

    Filgrastim

    Other Types

    6.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Tablet

    Capsule

    Other Products

    6.3. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oncological Diseases

    Blood Disorders

    Chronic And Autoimmune Disorders

    Other Applications

    7. G-CSF (Granulocyte Colony Stimulating Factors) Market Regional And Country Analysis

    7.1. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market

    8.1. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China G-CSF (Granulocyte Colony Stimulating Factors) Market

    9.1. China G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    9.2. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India G-CSF (Granulocyte Colony Stimulating Factors) Market

    10.1. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market

    11.1. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    11.2. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market

    12.1. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market

    13.1. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market

    14.1. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    14.2. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

    15.1. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    15.2. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK G-CSF (Granulocyte Colony Stimulating Factors) Market

    16.1. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market

    17.1. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France G-CSF (Granulocyte Colony Stimulating Factors) Market

    18.1. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market

    19.1. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market

    20.1. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market

    21.1. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    21.2. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market

    22.1. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America G-CSF (Granulocyte Colony Stimulating Factors) Market

    23.1. North America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    23.2. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA G-CSF (Granulocyte Colony Stimulating Factors) Market

    24.1. USA G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    24.2. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market

    25.1. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    25.2. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America G-CSF (Granulocyte Colony Stimulating Factors) Market

    26.1. South America G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    26.2. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market

    27.1. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market

    28.1. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    28.2. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market

    29.1. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market Overview

    29.2. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape And Company Profiles

    30.1. G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Landscape

    30.2. G-CSF (Granulocyte Colony Stimulating Factors) Market Company Profiles

    30.2.1. Amgen Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Coherus Biosciences Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Sandoz

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Biocon/Mylan

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Teva Pharmaceuticals Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. G-CSF (Granulocyte Colony Stimulating Factors) Market Other Major And Innovative Companies

    31.1. Chugai Pharma

    31.2. Intalfarmaco Group

    31.3. Pfizer

    31.4. Sun Pharmaceutical Industries Limited

    31.5. BeyondSpring Inc.

    31.6. Kyowa Hakko Kirin Co. Ltd

    31.7. BioCad

    31.8. Stada Arzneimittel

    31.9. Dong-A Socio Group

    31.10. Dr. Reddy's Laboratories

    31.11. Celltrion Inc.

    31.12. Emcure Pharmaceuticals

    31.13. Accord Healthcare UK

    31.14. Intas Pharmaceuticals

    31.15. Spectrum Pharmaceuticals

    32. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Benchmarking

    33. Global G-CSF (Granulocyte Colony Stimulating Factors) Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The G-CSF (Granulocyte Colony Stimulating Factors) Market

    35. G-CSF (Granulocyte Colony Stimulating Factors) Market Future Outlook and Potential Analysis

    35.1 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Countries Offering Most New Opportunities

    35.2 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Segments Offering Most New Opportunities

    35.3 G-CSF (Granulocyte Colony Stimulating Factors) Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Amgen Inc. Financial Performance
  • Table 75: Coherus Biosciences Inc. Financial Performance
  • Table 76: Sandoz Financial Performance
  • Table 77: Biocon/Mylan Financial Performance
  • Table 78: Teva Pharmaceuticals Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Amgen Inc. Financial Performance
  • Figure 75: Coherus Biosciences Inc. Financial Performance
  • Figure 76: Sandoz Financial Performance
  • Figure 77: Biocon/Mylan Financial Performance
  • Figure 78: Teva Pharmaceuticals Inc. Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Biosimilars Market 2022 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), And By Region, Opportunities And Strategies – Global Forecast To 2031
View Report
Hepatitis Drugs Global Market Report 2024 – By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents), By Route Of Administration (Oral, Injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Protein Expression Global Market Report 2024 – By Protein Expression (Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression), By Product (Reagents, Competent Cells, Expression vectors, Services, Instruments), By Application (Therapeutic, Industrial, Research), By End Use (Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Hematology Analyzers and Reagents Global Market Report 2024 – By Product (Hematology Analyzers, Hemostasis Analyzers, Plasma Protein Analyzers, Hemoglobin Analyzers, Erythrocyte Sedimentation Rate Analyzer, Coagulation Analyzer, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains), By Applications (Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications), By End User (Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Colorectal Cancer Drugs Global Market Report 2024 – By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL– Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Class (Immunotherapy, Chemotherapy, Other Classes), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Therapeutic Proteins Global Market Report 2024 – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Function (Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics), By Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Thyroid Cancer Drugs Global Market Report 2024 – By Drug Type (Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types), By Type (Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types), By End Users (Hospitals, Oncology Clinics, Research Organizations, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the G-CSF (granulocyte colony stimulating factors) market?

G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumours, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it. For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here

How will the G-CSF (granulocyte colony stimulating factors) market drivers and restraints affect the G-CSF (granulocyte colony stimulating factors) market dynamics? What forces will shape the G-CSF (granulocyte colony stimulating factors) industry going f

The G-CSF (granulocyte colony stimulating factors) market growth is aided by increasing prevalence of cancer. However, some G-CSF (granulocyte colony stimulating factors) market restraints include high cost. For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here

What is the forecast market size or the forecast market value of the G-CSF (granulocyte colony stimulating factors) market?

The G-CSF (granulocyte colony stimulating factors) market is expected to reach $9.94 billion in 2027 at a rate of 4.2%. For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here

How is the G-CSF (granulocyte colony stimulating factors) market segmented?

The global G-CSF (granulocyte colony stimulating factors) market is segmented as
1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex)
2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications
3) By Product: Tablet, Capsule, Other Products
For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here

Which region has the largest share of the G-CSF (granulocyte colony stimulating factors) market? What are the largest region's market size and growth rate?

North America was the largest region in the G-CSF (granulocyte colony stimulating factors) market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the G-CSF (granulocyte colony stimulating factors) market?

Key competitors in the G-CSF (granulocyte colony stimulating factors) market are, BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories, Celltrion Inc., Emcure Pharmaceuticals. For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here.

What are the key trends in the G-CSF (granulocyte colony stimulating factors) market?

Major trends influencing the G-CSF (granulocyte colony stimulating factors) market include focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For further insights on the G-CSF (granulocyte colony stimulating factors) market, request a sample here.

What are the major opportunities in the G-CSF (granulocyte colony stimulating factors) market? What are the strategies for the G-CSF (granulocyte colony stimulating factors) market?

For detailed insights on the major opportunities and strategies in the G-CSF (granulocyte colony stimulating factors) market, request a sample here.

How does the G-CSF (granulocyte colony stimulating factors) market relate to the overall economy and other similar markets?

For detailed insights on G-CSF (granulocyte colony stimulating factors) market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the G-CSF (granulocyte colony stimulating factors) industry?

For detailed insights on the mergers and acquisitions in the G-CSF (granulocyte colony stimulating factors) industry, request a sample here.

What are the key dynamics influencing the G-CSF (granulocyte colony stimulating factors) market growth? SWOT analysis of the G-CSF (granulocyte colony stimulating factors) market.

For detailed insights on the key dynamics influencing the G-CSF (granulocyte colony stimulating factors) market growth and SWOT analysis of the G-CSF (granulocyte colony stimulating factors) industry, request a sample here.